Source comparison
Comparison: MK-677 vs Injectable Growth Hormone Secretagogues
The table below compares MK-677 bioavailability against standard injectable GH-releasing peptides across key pharmacokinetic and practical parameters. Bioavailability 60–80% ~100% (bypasses GI) MK-677 achieves near-injectable efficiency orally. Eliminating rec
This comparison does not assign a generated winner or score.
- The table below compares MK-677 bioavailability against standard injectable GH-releasing peptides across key pharmacokinetic and practical parameters.
- Bioavailability
- 60–80%
- ~100% (bypasses GI)
- MK-677 achieves near-injectable efficiency orally. Eliminating reconstitution and injection barriers
- Half-Life
- 4–6 hours
- 20–30 minutes
- 6–8 days (DAC variant)
- 60–90 minutes
- MK-677's moderate half-life allows once-daily dosing; short-acting injectables require multiple daily doses
- GH Pulse Duration
- 6–8 hours primary, 12–16 hour secondary pulse
- 90–120 minutes
- Sustained elevation over 7 days
- 2–3 hours
- MK-677 produces prolonged GH response from single administration
- IGF-1 Elevation Timeline
- 60–90% increase by week 4
- 40–60% increase (requires daily dosing)
- 80–120% increase (weekly dosing)
- 30–50% increase (requires multiple daily doses)
- MK-677 delivers robust IGF-1 response without injection frequency
- Gastric Stability
- High (non-peptide structure)
- N/A (not orally active)
- Only MK-677 resists pepsin degradation
- Administration Complexity
- Single capsule
- Reconstitution + injection
- MK-677 eliminates cold chain, sterile technique, and disposal requirements